ELOX - Company ID 0001035354
Eloxx Pharmaceuticals, Inc. trades as ELOX. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$6.00M. This page tracks Eloxx Pharmaceuticals, Inc. through 1,006 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-06-17 |
| SCHEDULE 13G | - | 2026-06-17 |
| Insider trade | 4 | 2026-06-17 |
| New insider ownership | 3 | 2026-06-17 |
| SCHEDULE 13G | - | 2026-06-16 |
| SCHEDULE 13G | - | 2026-06-16 |
| SCHEDULE 13G | - | 2026-06-15 |
| Insider trade | 4 | 2026-06-10 |
The largest companies sharing Eloxx Pharmaceuticals, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Eloxx Pharmaceuticals, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Eloxx Pharmaceuticals, Inc. reported a net loss of $6.00M.